eCOA implementation
Common missteps when deploying eCOAs in clinical trials
Sometimes when teams deploy eCOA (electronic Clinical Outcome Assessment) in clinical trials, challenges can arise with operational planning, protocol design decisions, or workflow alignment. Below are some of the most common missteps observed across sponsors, CROs, and investigative sites.
1. Treating eCOA as a late-stage add-on
Many teams wait until protocol finalization or even after startup to plan eCOA implementation.
Why this causes problems
- Instrument licensing or translations may not be ready
- Build timelines get compressed
- Protocol schedules may not align with electronic workflows
Best practice
Plan eCOA during protocol design, especially when selecting instruments and defining visit schedules.
eCOA standards and KPIs to include in your next RFI
According to Gartner, a request for information, or a request for proposal, is defined as “both the process and documentation used in soliciting bids for potential business or IT solutions required by an enterprise or government agency. The RFI document typically outlines a statement of requirements (SOR) to be met by prospective respondents wishing to make a bid to deliver the required solutions. It might cover products and/or services to meet the given requirements.”
Yet, for anyone entering into a long-term business agreement, a well-written RFI can do so much more than just assess and collect vendor capabilities.
For the last decade, Medable has been transforming the capabilities of organizations across clinical research using the latest in new technologies. In this time, we’ve learned the best RFIs are able to define what success looks like, create alignment on measurable outcomes, and establish accountability on roles and responsibilities well before a contract is ever signed. When done correctly, it becomes a decision-making framework that offers clear vision to both organizations.
Recently, Medable received two RFIs around eCOA from top pharmaceutical organizations. They stood out to us because they were structured around performance, not promises, a distinction that makes all the difference.
Paper COAs in 2026? It’s not “cheaper,” it’s riskier
eCOA’s time has come. The market is currently estimated to be worth $2.3 billion, with projections showing it reaching nearly $5 billion by 2030. Despite this, paper still plays a prominent role for some clinical trials today.
At first glance, paper may seem simple and familiar, even economical. However, in today’s regulatory and operational environment, paper COAs are not a risk averse choice when held to the standards of what sponsors, CROs, and regulators are looking for trial data to prove.
Common eCOA implementation pitfalls and how to avoid them
The global eCOA (electronic clinical outcome assessment) solutions market was valued at over two billion dollars in 2025, and is projected to expand rapidly over the coming decade, driven by increased clinical trial activity, digital transformation efforts, and the integration of mobile, cloud, and AI-enabled tools for outcome measurement.
This growth reflects not just broader industry digitization, but an evolving expectation: that outcome data should be accurate, audit-ready through validated systems and controlled operational processes, and capable of supporting decentralized workflows.As more sponsors and CROs incorporate eCOA into their trial strategies and regulators continue to emphasize electronic data integrity the stakes of successful implementation have never been higher.
Yet with greater adoption comes greater complexity: pitfalls around site burden, mid-study amendments, device logistics, and training gaps can undermine even the most advanced platforms if not thoughtfully addressed.
The good news? These common challenges can be anticipated and managed with practical, operationally aligned planning turning eCOA from a source of friction into a strategic advantage for trial success.
The role of eCOAs and wearables in modern oncology clinical trials
In the rapidly evolving landscape of oncology clinical trials, the integration of electronic Clinical Outcome Assessments (eCOA) and wearable technologies is revolutionizing how data is collected and patient experiences are monitored. These technologies offer unprecedented opportunities to enhance data quality, improve patient engagement, and enable real-time tracking of treatment efficacy and side effects. This blog post delves into the pivotal roles that eCOA and wearables play in modern oncology clinical trials, highlighting their impact on patient-centric research and the advancement of cancer care.
Top technical considerations with eCOA in clinical trials
Explore the prevalent challenges encountered in eCOA clinical trials, from technical issues and patient adherence to data security and regulatory adherence, and discover strategies for mitigation.
Implementing eCOA software in clinical trials: A How-to guide
Electronic clinical outcome assessments (eCOAs) have revolutionized clinical trials, offering significant advantages over traditional paper-based methods. By enhancing data quality, streamlining data collection, improving patient engagement, and enabling real-time data access, eCOAs have become indispensable tools in modern clinical research. However, successful eCOA implementation requires careful planning, meticulous execution, and a deep understanding of the regulatory landscape. This comprehensive guide provides a detailed roadmap for implementing eCOAs effectively, covering key aspects from study design to future trends.